#United States #financial results #South San Francisco #Rigel Pharmaceuticals #Conference Call

Rigel Pharmaceuticals to Report Q3 2026 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has announced that it will reveal its financial achievements for the third quarter of 2026 after the market closes on November 5, 2026. Following the report, there will be a live conference call along with a webcast to provide a detailed overview of the company’s performance during the period.

The live session is scheduled for 4:30 PM Eastern Time (1:30 PM Pacific Time), during which Rigel’s senior management team is expected to present insights into the financial results and update stakeholders on the company’s current and future business strategies. Participants wishing to join the conference call can do so by dialing:

• - 877-407-3088 (domestic)
• - 201-389-0927 (international)

Additionally, all interested parties can access the webcast via the Investor Relations section of Rigel’s official website at www.rigel.com. The webcast will also be archived, allowing for replays to be available for 90 days after the event.

Company Overview

Rigel Pharmaceuticals, headquartered in South San Francisco, California, was established in 1996 and is dedicated to developing innovative therapies aimed at improving the lives of patients facing hematologic diseases and cancer. Over the years, Rigel has made significant strides in the biotechnology sector, focusing on novel treatments that align with patient needs and market demands.

Innovation in Oncology and Hematology

Rigel’s portfolio includes initiatives focusing on hematologic disorders along with various types of cancer, with a commitment to discovering, developing, and commercializing its therapeutic inventions. Their pipeline reflects ongoing advancements in medical science, showcasing the company’s aim to bring transformative options to the market.

For more information about Rigel and its marketed products, as well as its future pipeline offerings, stakeholders can visit www.rigel.com. With this upcoming event, investors and analysts will eagerly await insights into how Rigel is managing economic pressures and what innovation trails the company is pioneering in its therapeutic areas.

Contact Information

For any inquiries relating to the conference call, the investor relations department can be contacted at 650-624-1232 or via email at [email protected]. Media representatives can reach out to David Rosen from Argot Partners by calling 646-461-6387 or sending an email to [email protected].

As the financial reporting date approaches, Rigel Pharmaceuticals is poised to share significant updates that will elucidate its trajectory and reaffirm its commitments within the biotechnology arena. Stakeholders should mark their calendars for this informative event, reinforcing Rigel’s commitment to transparency and investor engagement.